Inhibrx Biosciences, Inc. (INBX)
NASDAQ:INBX
Want to see INBX full AI Analyst Report?
Top Page
Inhibrx Biosciences Inc
(NASDAQ:INBX)
Select Model
Select Model
Rating:54Neutral
Price Target:
$118.00
▲(38.30% Upside)
Action:Reiterated
Date:05/15/26
The score is held down primarily by weak financial performance (large losses, heavy cash burn, and negative equity). Offsetting this are supportive technical trends and positive recent clinical pipeline updates (Phase 2 efficacy signals and advancement plans). Valuation remains difficult to assess on earnings given ongoing losses.
Positive Factors
Clinical efficacy — INBRX-106
Robust Phase 2 ORR (44% vs 21.4%) and a planned Phase 3 start in Q3 2026 materially de-risk INBRX-106. If confirmed, the asset could become a first-in-class IO costimulatory agent, enabling registrational pathways, partnerships, and durable commercial opportunities across IO indications.
Negative Factors
High cash burn
Sustained negative operating and free cash flow (~-$131.9M TTM) shows the company is materially cash consumptive. Persistent burn increases dependency on external capital, raising dilution risk and potentially constraining strategic flexibility if clinical timelines slip or fundraising conditions worsen.
Read all positive and negative factors
Positive Factors
Negative Factors
Clinical efficacy — INBRX-106
Robust Phase 2 ORR (44% vs 21.4%) and a planned Phase 3 start in Q3 2026 materially de-risk INBRX-106. If confirmed, the asset could become a first-in-class IO costimulatory agent, enabling registrational pathways, partnerships, and durable commercial opportunities across IO indications.
Read all positive factors
Inhibrx Biosciences Inc (INBX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.49B
Dividend YieldN/A
Average Volume (3M)595.02K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue Growth550.00%
EPS Growth-107.04%
CountryUS
Employees156
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.39
Shares Outstanding14,671,186
10 Day Avg. Volume645,471
30 Day Avg. Volume595,023
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)153.07
Price to Sales (P/S)941.13
P/FCF Ratio-9.42
Enterprise Value/Market Cap0.90
Enterprise Value/Revenue1.02K
Enterprise Value/Gross Profit-2.87K
Enterprise Value/Ebitda-11.36
Forecast
1Y Price Target
$277.50Price Target Upside225.25% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-7.83
Revenue Forecast (FY)N/A
Inhibrx Biosciences Inc Business Overview & Revenue Model
Company Description
Inhibrx Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of biologic therapeutics for people with life-threatening conditions. Its therapeutic candidates includes INBRX-109, a tetravalent therapeutic candid...
How the Company Makes Money
null...
Inhibrx Biosciences Inc Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
25
Negative
Cash Flow
10
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 1.30M | 1.30M | 200.00K | 1.80M | 2.19M | 7.13M |
| Gross Profit | -463.00K | -1.18M | -2.08M | 609.00K | -107.99M | 4.44M |
| EBITDA | -117.09M | -132.54M | 1.70B | -206.69M | -125.82M | -75.37M |
| Net Income | -130.19M | -140.06M | 1.69B | -241.36M | -145.23M | -81.77M |
Balance Sheet | ||||||
| Total Assets | 183.97M | 146.48M | 180.77M | 307.89M | 290.88M | 150.45M |
| Cash, Cash Equivalents and Short-Term Investments | 161.66M | 124.22M | 152.60M | 277.92M | 273.87M | 131.30M |
| Total Debt | 5.90M | 107.01M | 8.05M | 210.14M | 207.10M | 72.14M |
| Total Liabilities | 205.00M | 138.49M | 47.18M | 264.39M | 232.82M | 98.07M |
| Stockholders Equity | -21.04M | 7.99M | 133.58M | 43.50M | 58.06M | 52.38M |
Cash Flow | ||||||
| Free Cash Flow | -131.94M | -129.82M | -197.01M | -197.90M | -115.99M | -81.19M |
| Operating Cash Flow | -131.93M | -129.79M | -194.41M | -193.31M | -115.30M | -80.32M |
| Investing Cash Flow | -7.00K | -28.00K | -2.60M | -4.59M | -686.00K | -809.00K |
| Financing Cash Flow | 77.07M | 101.45M | 71.68M | 201.96M | 258.55M | 83.77M |
Inhibrx Biosciences Inc Technical Analysis
Positive
85.32
Price Trends
93.73
Positive
85.21
Positive
68.70
Positive
Market Momentum
2.33
Positive
44.50
Neutral
17.25
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBX, the sentiment is Positive. The current price of 85.32 is below the 20-day moving average (MA) of 120.89, below the 50-day MA of 93.73, and above the 200-day MA of 68.70, indicating a neutral trend. The MACD of 2.33 indicates Positive momentum. The RSI at 44.50 is Neutral, neither overbought nor oversold. The STOCH value of 17.25 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for INBX.
Inhibrx Biosciences Inc Risk Analysis
Inhibrx Biosciences Inc disclosed 88 risk factors in its most recent earnings report. Inhibrx Biosciences Inc reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Inhibrx Biosciences Inc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
55 Neutral | $1.59B | -6.06 | -40.99% | ― | -73.07% | -2335.85% | |
55 Neutral | $585.43M | -8.62 | -60.42% | ― | ― | 26.28% | |
54 Neutral | $1.49B | -7.83 | -563.89% | ― | 550.00% | -107.04% | |
53 Neutral | $818.56M | -11.41 | -36.61% | ― | -75.91% | -173.33% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $514.63M | 3.99 | -49.88% | ― | -57.99% | -37.06% | |
50 Neutral | $233.12M | -1.70 | -2781.56% | ― | 289.94% | 16.60% |
* Healthcare Sector Average
INBX
Inhibrx Biosciences Inc
101.32
88.19
671.67%
PRTA
Prothena
9.83
3.25
49.39%
CTMX
CytomX Therapeutics
3.76
1.53
68.61%
HUMA
Humacyte
1.05
-1.48
-58.50%
GLUE
Monte Rosa Therapeutics
18.81
14.82
371.43%
CADL
Candel Therapeutics
7.99
2.39
42.68%
Inhibrx Biosciences Inc Corporate Events
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences Reports Positive Interim Phase 2 Results
Positive
May 11, 2026
On May 11, 2026, Inhibrx Biosciences reported positive interim Phase 2 data from its HexAgon trial evaluating INBRX-106, a hexavalent OX40 agonist, plus pembrolizumab versus pembrolizumab alone in first-line, PD-L1 high metastatic or unresectable ...
Business Operations and StrategyProduct-Related Announcements
Inhibrx Biosciences Highlights Promising Ozekibart Colorectal Cancer Data
Positive
Apr 21, 2026
On April 21, 2026, Inhibrx Biosciences reported updated interim results from a Phase 1/2 trial of its DR5 agonist antibody ozekibart (INBRX-109) combined with FOLFIRI in locally advanced or metastatic, unresectable colorectal cancer. As of the Apr...
Business Operations and StrategyFinancial Disclosures
Inhibrx Biosciences Highlights 2026 Pipeline and Strategy
Positive
Feb 23, 2026
On February 23, 2026, Inhibrx Biosciences posted an updated corporate investor presentation outlining its current programs, financial position, and upcoming catalysts, which it plans to use in meetings with the investment community. The materials ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.